Experts are increasingly concentrating on retatrutide peptides , a novel dual agonist targeting both GLP-1 and GIP receptors. This particular approach appears to provide significant potential for weight management and associated metabolic issues . Early scientific investigations have demonstrated encouraging results, indicating a possible change i